Status:
COMPLETED
Efficacy of Liposomal Bupivacaine Versus 0.25% Bupivacaine for Laparoscopic Urologic Surgery
Lead Sponsor:
Knight, Richard, M.D.
Conditions:
Pain, Postoperative
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A prospective, randomized comparison of bupivacaine to liposomal bupivacaine given by local injection at all the wound sites in patients undergoing robotic-assisted or laparoscopic urologic surgeries ...
Detailed Description
Liposomal bupivacaine was developed to extend the duration of efficacy of bupivacaine from the typical 6 - 8 hours up to 72 hours. The prolonged duration of liposomal bupivacaine was initially demonst...
Eligibility Criteria
Inclusion
- At least 18-years-old, undergoing laparoscopic urologic surgery.
Exclusion
- Pregnant and/or nursing mothers.
- Allergy to bupivacaine.
Key Trial Info
Start Date :
December 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
206 Patients enrolled
Trial Details
Trial ID
NCT02222129
Start Date
December 1 2012
End Date
December 1 2013
Last Update
April 16 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Baptist Health System
San Antonio, Texas, United States, 78205
2
Methodist Healthcare System
San Antonio, Texas, United States, 78229